34 days to first decision for reviewed manuscripts only
27 days to first decision for all manuscripts
56 days from submission to acceptance
12 days from acceptance to publication
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substa...
Citation: Experimental Hematology & Oncology 2020 9:26